绥美凯对艾滋病患者有效果没？

Is it effective for AIDS patients?

Trimax contains three ingredients: abacavir, lamivudine and dolutegravir. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs); dolutegravir is an integrase inhibitor (INIs). Existing research shows that one year (48 weeks) after HIV infection treatment, 93% of HIV-infected patients turned negative. 

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP), a deoxyguanosine-5'-triphosphate (dGTP) analogue, under the action of intracellular enzymes. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA. Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity. 

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%.

From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutation sites is significantly less than that of the other two drugs, making it less likely to develop resistance, and the effect is better!

Recommended related hot articles: /newsDetail/71861.html